v3.26.1
SEGMENT REPORTING
6 Months Ended
Jun. 30, 2026
SEGMENT REPORTING  
SEGMENT REPORTING

NOTE 7 – SEGMENT REPORTING:

a.The Company operates in one reportable segment: clinical development. The clinical development segment facilitates the development of potential new drug compounds, and its business is unified for the purpose of valuing its performance.

Management does not segregate its business for internal reporting. The Company's Chief Operating Decision Maker (“CODM”), who is the CEO, evaluates the Company's performance based on net losses its unified internal reporting, which is consistent with the presentation in the Company’s financial statements.

Net loss is used to make key operating decisions, such as allocation of resources between the company’s cost.

The CODM uses many quantitative and qualitative factors, including net loss and quarterly cash burn, to benchmark the Company against its competitors. The competitive analysis, along with monitoring budgeted versus actual results, is used to assess segment performance and establish management’s compensation.

Significant segment expenses are presented in the Company’s statements of operations. Additional disaggregated significant segment expenses on a functional basis that are not separately presented on the Company’s statements of operations are presented below:

Three Months Ended June 30

Six Months Ended June 30

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

R&D Employee Expenses

$

1,961

 

$

1,639

 

$

4,026

 

$

3,356

R&D Clinical Trial Expenses

1,955

 

1,605

3,167

 

2,641

R&D Manufacturing

766

356

1,595

832

R&D License Fees

1

1

438

G&A Professional Fees

1,537

2,045

2,694

3,002

G&A Employee Expenses

568

472

1,169

974

G&A Insurance and other

408

465

 

804

894

Other Segment Items *

(176)

 

(248)

 

(386)

 

(471)

Segment Loss

$

7,020

 

$

6,334

$

13,070

 

$

11,666

* - Other Segment Items included in net loss include finance income.